Moderna, Inc. Deferred Federal Income Tax Expense (Benefit)
Moderna, Inc. (MRNA) reported Deferred Federal Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-02-20
- Moderna, Inc. deferred federal income tax expense (benefit) for fiscal 2025 was $0.00.
- Moderna, Inc. deferred federal income tax expense (benefit) for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Moderna, Inc. deferred federal income tax expense (benefit) for fiscal 2023 was $888.00M.
- Moderna, Inc. deferred federal income tax expense (benefit) for fiscal 2022 was -$569.00M.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month | Deferred Federal Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-20 | |
| 2024-12-31 | $0.00 10-K · filed 2026-02-20 | |
| 2023-12-31 | $888.00M 10-K · filed 2026-02-20 | |
| 2022-12-31 | -$569.00M 10-K · filed 2025-02-21 | |
| 2021-12-31 | -$288.00M 10-K · filed 2024-02-23 | |
| 2020-12-31 | $0.00 10-K · filed 2023-02-24 | |
| 2019-12-31 | -$1.00M 10-K · filed 2022-02-25 | -$1.20M 10-K · filed 2020-02-27 |
| 2018-12-31 | $0.00 10-K · filed 2021-02-26 | |
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 | |
| 2016-12-31 | $288.00K 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |